Skip to content
OpenCapital
Get started

Trevi Therapeutics, Inc. TRVI Payments for finance leases

Payments for finance leases at other companies

LQD
Liquidia CorporationLQDA
$0-100%

Other financials

Income statement

See full
Operating income-$14.9M-30.0%
Net income-$13.2M-27.6%
EPS (diluted)-$0.090.0%

Balance sheet

See full
Cash & equivalents$19.4M+0.2%
Total debt$682.0K-28.7%
Total equity$172.1M+73.1%
Total assets$179.6M+67.8%

Cash flow

See full
Operating cash flow-$16.7M-23.8%
CapEx$102.0K—
Free cash flow-$16.8M—

Valuation

See full
Market cap$2.47B+152%
Enterprise value$2.45B+157%

Returns & leverage

See full
Return on equity-33.6%-9.4pp
Debt / equity0×0.0×
Current ratio24.8×+9.4×

Where this comes from

Reported directly by Trevi Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeasePrincipalPayments.

The official record: Trevi Therapeutics, Inc.’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Trevi Therapeutics, Inc.'s payments for finance leases.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Trevi Therapeutics, Inc.'s payments for finance leases?
Trevi Therapeutics, Inc. (TRVI) reported payments for finance leases of $0 in Q4 2025.
How has Trevi Therapeutics, Inc.'s payments for finance leases changed year-over-year?
Trevi Therapeutics, Inc.'s payments for finance leases decreased by 100.0% year-over-year, from $31K to $0.
What is the long-term trend for Trevi Therapeutics, Inc.'s payments for finance leases?
Over 2 years (2023 to 2025), Trevi Therapeutics, Inc.'s payments for finance leases has grown at a -66.1% compound annual growth rate (CAGR), from $96K to $11K.
What does payments for finance leases mean?
Principal payments on finance lease obligations, reducing the lease liability on the balance sheet.